Advanced searches left 3/3

Sentinel Node Biopsy - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 13 July 2022

* If you want to update the article please login/register

Feasibility of Sentinel Lymph Node Biopsy in Rectal Cancer

One of the challenges in treating rectal cancer is determining which patients will benefit from less radical surgery, which is safer and better tolerated. However, it does not eliminate lymph nodes where cancer cells can have spread, but it does not exclude lymph nodes where cancer cells may have spread. If lymph nodes containing cancer are left behind, the disease may recur. Sentinel lymph node biopsy is a procedure used to surgically remove the first lymph node, where cancer cells are spread. Investigators will determine whether the Sienna+/Sentimag system correctly identifies the sentinel lymph node, and whether the node can be removed surgically or surgically. Patients in Oxford hospitals about to have rectal cancer surgery will be recruited by the investigators. During endoscopy, patients will receive a patch of magnetic tracer prior to surgery. A magnetic probe will be used to locate the sentinel lymph node in the tissue around the rectum during or after surgery, depending on the complexity of the procedure.

Source link: https://clinicaltrials.gov/ct2/show/NCT02445456


Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)

The first trial visit before NST will take place in order to provide the patient with detailed information about the study, its objectives, the VAB procedure, and its risks. In the operating room, the VAB's sentinel lymph node biopsy will be performed. The objective of the study will determine whether coincidence of the clinical complete or partial response with pathological complete response. In comparison to a standard pathological examination of the surgical specimen and regional lymph nodes, it was determined that the likelihood of finding a residual tumor in the mammary gland using a Vacuum-assisted biopsy or another form of core biopsy, as well as the detection of metastases in regional lymph nodes. Patients with clinical complete response after neoadjuvant systemic therapy, which included residual disease in patients with clinically poor response, were compared to patients with pathologically clear responses. With a reported pathological clear response using a tumor bed biopsy and targeted biopsy of sentinel lymph nodes, it is possible to establish an algorithm for treating patients with clinically high response, with a confirmed pathological positive result. After NST, Ultrasound guided VAB will be performed on breast cancer patients with no detectable reaction after NST. The VAB specimen and VAB representative of former tumor region are expected to be categorized as follows: Residual tumor cells in the VAB specimen and VAB representative of former tumor region No residual tumor cells were found in the VAB specimen, but VAB specimens were not representative of former tumor locations.

Source link: https://clinicaltrials.gov/ct2/show/NCT04293796

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions